VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

LLMC 2020 | New therapeutic options for low-risk MDS

Sangmin Lee, MD, Weill Cornell Medical College, New York City, NY, outlines discusses recently approved treatments for low-risk myelodysplastic syndromes (MDS). He discusses the approval of luspatercept for low-risk MDS patients with the SF3B1 mutation as a result of the Phase III MEDALIST clinical trial (NCT02631070), and the approval of an oral form of the hypomethylating agent decitabine as a result of the Phase III ASCERTAIN trial (NCT03306264). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Disclosures

Consultancy: AstraZeneca, BMS, Jazz, Roche Diagnostics
DSMB membership: Helsinn

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter